Peptide Schedule
KPV3 residuesKPVEach bubble = one amino acid. Size = residue mass. Color = chemical class.KPV
Benefits
About KPV
KPV is a naturally occurring anti-inflammatory tripeptide (Lysine-Proline-Valine) derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH). It powerfully reduces inflammation by inhibiting NF-κB and inflammatory cytokines. It's particularly effective for gut inflammation — IBS, colitis, and leaky gut — and can be taken both by injection and orally (oral capsules deliver directly to the gut lining).
Who Should Consider KPV
- Adults with inflammatory bowel disease (ulcerative colitis or Crohn's)
- Individuals with chronic gut inflammation, IBS, or leaky gut syndrome
- Adults seeking targeted intestinal anti-inflammatory support
- Patients with skin inflammatory conditions (dermatitis, psoriasis)
- Adults recovering from GI infections or antibiotic-related gut damage
How KPV Works
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH). Unlike full-length α-MSH, KPV does not act through melanocortin receptors. Instead, it enters cells via the PepT1 di/tripeptide transporter, which is normally expressed in the small intestine and becomes upregulated in inflamed colonic tissue during IBD. Once inside the cell, KPV inhibits NF-κB activation at nanomolar concentrations, blocking the nuclear translocation of this master inflammatory transcription factor. It also suppresses MAP kinase signaling pathways. The downstream result is reduced production of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8, while anti-inflammatory IL-10 is preserved or upregulated. KPV also decreases expression of adhesion molecules and chemokine receptors on immune cells, limiting inflammatory cell recruitment to damaged tissue. In colonic epithelial cells, KPV promotes mucosal healing by reducing epithelial apoptosis and restoring barrier integrity. Because PepT1 expression increases during intestinal inflammation, KPV is preferentially taken up by the cells that need it most — creating a natural targeting effect. This PepT1-dependent uptake has been confirmed in both Caco2-BBE intestinal epithelial cells and immune cells including macrophages.
What to Expect
Body adjusts to the peptide. Some users report reduced bloating and mild improvement in GI comfort within the first week. Establish consistent daily dosing routine.
Anti-inflammatory effects become noticeable. Reduced gut pain, improved stool consistency, and decreased bloating reported by most users. Inflammatory markers may begin to improve.
Significant reduction in gut inflammation symptoms. Users with colitis or IBS typically report meaningful improvement in flare frequency and severity. Mucosal healing is underway.
Peak therapeutic benefit for most users. Gut barrier integrity improves. Systemic inflammatory markers (CRP, calprotectin) often show measurable reduction. Skin inflammation also improves if present.
Maintenance phase. Most protocols recommend cycling off after 8 weeks. Benefits typically persist for several weeks after discontinuation. Repeat cycles as needed for flare management.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 200mcg | Daily |
| Moderate | 500mcg | Daily |
| Aggressive | 1mg | Daily |
Note: Anti-inflammatory tripeptide (Lys-Pro-Val) derived from α-MSH. Powerfully reduces gut inflammation. Can also be taken orally in capsules for direct gut effect. Commonly cycled 4-8 weeks.
Pharmacokinetics
Source: Estimated from rapid plasma degradation kinetics of small tripeptides; KPV has a plasma half-life under 30 minutes but exerts prolonged intracellular effects via PepT1 uptake (PMID 18061177)
Loading the interactive decay curve.
Side Effects
Very well-tolerated. Minimal reported side effects. Mild injection site reactions possible.
Contraindications
- Pregnancy or breastfeeding — no human safety data in these populations
- Known hypersensitivity to KPV or α-MSH-derived peptides
- Active malignancy — effects on tumor immune surveillance not studied
- Children and adolescents under 18 — not studied in pediatric populations
- Concurrent immunosuppressive therapy — potential for additive immune suppression
Drug Interactions
- Immunosuppressants (methotrexate, azathioprine, biologics) — potential additive immune suppression; monitor closely
- NSAIDs — while KPV may protect against NSAID-induced gut damage, combined anti-inflammatory effects should be monitored
- Corticosteroids — overlapping anti-inflammatory pathways; no direct interaction known but monitor for over-suppression of immune response
- Aminosalicylates (mesalamine, sulfasalazine) — no known interaction; may provide complementary benefit for IBD patients
- Anticoagulants — no known interaction, but monitor for injection site bruising with injectable form
Molecular Profile
Related Peptides
References
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation (Gastroenterology 2008)PubMed 18061177
- Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis (Mol Ther 2017)PubMed 28143741
- α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs (Ann Rheum Dis 2007)PubMed 17934097
- Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides (J Neuroimmunol 2003)PubMed 12750433
- Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model (Cell Mol Gastroenterol Hepatol 2017)PubMed 28174757
- Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists (Mol Cell Endocrinol 2012)PubMed 22837805